Login to Your Account



The Ruling: Supreme Court Overturns Prometheus Patents

By Mari Serebrov
Washington Editor

Wednesday, March 21, 2012
WASHINGTON – In a decision that will have biotechs reviewing their process patents, the Supreme Court Tuesday ruled that Prometheus Laboratories Inc.'s patents for calibrating the proper dosage of thiopurine drugs used to treat autoimmune diseases are not patentable because they involve laws of nature.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription